Plain Language Summary: This investigator‑initiated study, led by Innovative Hematology’s Dr. Kyle Davis with the guidance of Dr. Amy Shapiro, Dr. Sanjay Ahuja and the IHI research team, explores the use of emicizumab (Hemlibra) in individuals with mild hemophilia A. The study was supported by funding from Genentech.
The findings highlight the power of real-world evidence to inform everyday clinical care—demonstrating that select patients with mild hemophilia may benefit from preventive therapy and advancing the conversation around equitable access to treatment for hemophilia.
